冷冻保存与液态储存血小板治疗手术出血:CLIP-II随机非劣效性临床试验
CLIP-II多中心随机双盲非劣效性试验在11家澳大利亚三级医院比较冷冻保存与液态储存血小板治疗心脏手术出血,202例输血患者中冷冻组术后24小时胸管出血605 mL vs 液态组535 mL,几何均值比1.13(95%CI 0.96-1.34;P=0.07),因置信区间包含超过非劣效界值的出血,未确立非劣效性。
要点
- 冷冻保存血小板未达到预设的非劣效性阈值,止血效果未确立非劣效。
- 冷冻组术中及围术期总失血量几何均值比分别为1.42和1.31,红细胞、血浆及冷沉淀输注增加。
- 两组预设不良事件发生率无差异,但冷冻组拔管时间及ICU/住院时间更长。
核心结论
- 冷冻保存血小板在ICU入住后24小时止血效果上未达到预设的非劣效性阈值。
- 其他预设终点一致提示冷冻保存血小板止血效果减弱,但预设不良事件发生率相当。
研究设计与样本
- CLIP-II为多中心、随机、双盲、平行组非劣效性试验,2021年8月至2024年4月在11家澳大利亚三级医院入组,随访于2024年7月完成。
- 879例符合纳入标准的患者中排除182例、285例未同意,余412例中388例随机化,202例接受了研究血小板。
- 纳入血小板输注高风险患者,排除有深静脉血栓或肺栓塞史、凝血功能障碍、以及18至55岁RhD阴性或RhD状态未知的女性。
- 干预为术中或术后24小时内开始输注最多3单位O型冷冻保存血小板或常规液态储存血小板。
主要发现
- 202例输血患者平均(SD)年龄64.4(13)岁,75.7%为男性,61例(30.2%)接受非择期手术。
- 主要结局术后ICU入住后24小时内胸管出血:冷冻保存血小板组605 mL vs 液态储存血小板组535 mL,几何均值比(冷冻/液态)1.13(95%CI 0.96-1.34;P=0.07)。
- 因置信区间包含超过非劣效界值的出血,非劣效性未确立。
- 冷冻保存血小板输注与更高的术中及围术期总失血量相关,几何均值比(冷冻/液态)分别为1.42(95%CI 1.12-1.80)和1.31(95%CI 1.07-1.60),并增加红细胞、血浆及冷沉淀输注。
- 预设不良事件发生率无差异,但冷冻保存血小板组拔管时间及ICU/住院时间更长:中位(IQR)通气时间25.5小时(16.1-77.3)vs 23.6小时(13.1-52.8);中位(IQR)ICU住院时间3.8天(2.0-6.0)vs 3.0天(1.9-4.9);中位住院时间10.9天(7.87-17.0)vs 9.1天(6.9-14.9)。
关键数值与推荐
- 非劣效性预先定义为该期间出血增加不超过20%。
- 预先定义了5个次要结局和42个三级结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Liquid-stored platelets have a shelf-life of 5 to 7 days, limiting availability and resulting in wastage. OBJECTIVE: To assess the effectiveness and safety of dimethyl sulfoxide-cryopreserved platelets, which have a shelf-life of 2 years, as a treatment for cardiac surgery bleeding. DESIGN, SETTING, AND PARTICIPANTS: The Cryopreserved vs Liquid Platelets II (CLIP-II) trial was a multicenter, randomized, double-blind, parallel-group noninferiority trial, which enrolled patients between August 2021 and April 2024 at 11 Australian tertiary hospitals, with follow-up completed in July 2024. Patients at high risk of platelet transfusion were eligible. Patients were excluded if they had a history of deep vein thrombosis or pulmonary embolism, were coagulopathic, or were females aged 18 to 55 years who were rhesus D (RhD) negative or of unknown RhD status. Of 879 patients meeting inclusion criteria, 182 were excluded and 285 did not consent, leaving 412. Of these, 388 were randomized and 202 received study platelets. INTERVENTIONS: Patients received up to 3 units of either group O cryopreserved platelets or conventional liquid-stored platelets, commencing intraoperatively or in the first 24 postoperative hours. MAIN OUTCOMES AND MEASURES: The primary outcome was postsurgical chest drain bleeding within the first 24 hours following intensive care unit admission. Noninferiority was defined prospectively as less than 20% greater bleeding in this period. Five secondary and 42 tertiary outcomes were defined a priori. RESULTS: Of the 202 transfused patients (mean [SD] age, 64.4 [13] years; 75.7% male), 61 (30.2%) underwent nonelective surgery. The primary outcome did not differ between groups (605 mL in cryopreserved platelet group vs 535 mL in liquid-stored platelet group; ratio of geometric means [cryopreserved to liquid ratio], 1.13 [95% CI, 0.96-1.34]; P = .07). As the confidence interval includes bleeding exceeding the noninferiority margin, noninferiority was not established. Cryopreserved platelet transfusion was associated with higher intraoperative and total perioperative blood loss (ratio of geometric means [cryopreserved to liquid ratio], 1.42 [95% CI, 1.12-1.80]; 1.31 [95% CI, 1.07-1.60], respectively), and increased red cell, plasma, and cryoprecipitate transfusion. While there were no differences in the incidence of prespecified adverse events, patients receiving cryopreserved platelets experienced longer times to extubation and intensive care unit/hospital discharge (median [IQR] duration of ventilation, 25.5 hours [16.1-77.3] vs 23.6 hours [13.1-52.8]; median [IQR] intensive care unit length of stay, 3.8 days [2.0-6.0] vs 3.0 days [1.9-4.9]; median hospital length of stay, 10.9 days [7.87-17.0] vs 9.1 [6.9-14.9]). CONCLUSIONS AND RELEVANCE: Cryopreserved platelets did not meet the predefined threshold for noninferiority in hemostatic effectiveness at 24 hours after ICU admission. Additional predefined end points consistently indicated diminished hemostatic effectiveness, although prespecified adverse events were comparable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03991481.
引用
- Reade MC, Marks DC, Howe BD, et al. Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial. JAMA. 2026. PMID: 41360717. doi:10.1001/jama.2025.23355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。